Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Daily

Download Data

Immix Biopharma Inc Price to Book Ratio (P/B) on June 03, 2024: 1.85

Immix Biopharma Inc Price to Book Ratio (P/B) is 1.85 on June 03, 2024, a -23.76% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Immix Biopharma Inc 52-week high Price to Book Ratio (P/B) is 6.83 on December 15, 2023, which is 270.18% above the current Price to Book Ratio (P/B).
Immix Biopharma Inc 52-week low Price to Book Ratio (P/B) is 1.85 on June 03, 2024, which is 0.00% below the current Price to Book Ratio (P/B).
Immix Biopharma Inc average Price to Book Ratio (P/B) for the last 52 weeks is 3.46.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends